However, the risk of recurrence afterwards is high, resulting in 5-year overall survival (OS) rates between 40 and 78%.1–3 Therapeutic options and prospects for patients with metastatic melanoma have changed considerably in recent years, especially with the introduction of immune checkpoint inhibitors and BRAF and MEK inhibitors.4–10 These drugs have been proven to significantly improve OS in metastatic melanoma and have also shown promising results in the adjuvant setting. Here, MAP2K7 is linked to metastatic melanoma.